Background: This systematic analysis aspired to investigate the diagnostic and prognostic role of metastasis associated lung adenocarcinoma transcript 1 (MALAT1) in breast cancer. Methods: We conducted a search in PubMed, EMBASE, MEDLINE, Web of Science, CNKI, Wanfang and VIP databases to identify eligible articles, and combined the effect sizes using Stata 15.0 and Meta-Disc 1.4. Results: 19 articles were identifed in our study, including 9 diagnostic articles and 11 prognostic articles. For the diagnostic meta-analysis, the pooled specificity, sensitivity, diagnostic odds ratio, area under the curve of MALAT1 in confirming breast cancer were 0.77 (95% confidence interval (CI): 0.68–0.84), 0.81 (95% CI: 0.71–0.88), 14.09 (95% CI: 6.34–31.31) and 0.85 (95% CI: 0.82–0.88), separately. The subgroup analysis demonstrated that the diagnostic effect of MALAT1 in triple negative breast cancer was higher than in breast cancer. For the survival outcomes meta-analysis, patients with over-expression of MALAT1 had poor overall survival, recurrence free survival, metastasis-free survival, disease specific survival and disease free survival. Conclusion: MALAT1 may serve as a promising biomarker for diagnosis and prognosis for confirming breast cancer.
展开▼
